Progression Free Survival (PFS) & Overall Response Rate was calculated. Quality of life (QOL) was calculated monthly.

Results The median PFS was 4 months (3 mon–5 mon). The median ORR was 15% (13%-17%). Commonest toxicity was grade 2 anaemia. No grade 3 toxicity. Among QOL pain & vomiting improved most.

Conclusion OMCT is quite effective least toxic therapy in treating improved most. All secondary to disease progression. Among QOL pain & vomiting improved most. There were 10 deaths during follow-up. Median ORR was 15% (13%-17%). Commonest toxicity was grade 2 anaemia. No grade 3 toxicity. There were 10 deaths – none due to disease progression. Among QOL, pain & vomiting improved most.

OMCT is quite effective in treating advanced-stage ovarian cancer. However randomized trial required comparing it with single agent oral etoposide & best supportive care.